With hopes of dethroning Regeneron’s blockbuster eye drug franchise Eylea, Roche on Thursday announced the FDA has expanded the label of its own blockbuster eye drug Vabysmo (faricimab-svoa) to a third indication, this time for the treatment of macular edema following retinal vein occlusion (RVO).
